

# METABOLOMICS EXPANDS THE PRECISION ONCOLOGY TOOLBOX

Precision oncology has a variety of definitions. In the simplest terms, it is an approach that identifies and targets the molecular drivers of cancer cells and matches patients to therapeutic treatments that specifically block those drivers.

Because cancer is a genomic disease, genomic profiling is an undeniably important tool for precision oncology. It was central to identifying the molecular drivers of BRAF in melanoma and ALK in non-small cell lung cancer, for example.

Genomics, however, is frequently insufficient for identifying tumor-specific targets and delineating responders to targeted therapies. In fact, an assessment of the clinical utility of genomic and proteomic data across tumor types concluded that molecular data only slightly improved clinical predictions over and above standard clinical variables.<sup>1</sup>

This is because most cancers are the product of a cocktail of mutated genes operating collectively toward initiation, progression and maintenance. Separating the key oncogenic driver mutations from the less significant or passenger mutations is a major challenge.

What's more, many tumors demonstrate a plasticity/redundancy of signaling pathways that can be "re-routed" around a therapeutic blockage point to preserve key oncogenic functions (the use of BRAF inhibitors in metastatic melanoma is a prime example). This has led to the emergence of treatment resistance in targeted, genomic-focused therapeutics and forced clinicians to use multiple cancer therapeutics in combination in an effort to "short circuit" these alternate routes.

## Downstream Targeting to Improve Outcomes

To address these challenges, many researchers and oncologists have begun to advocate targeting signaling pathways further "downstream," where the signaling message directs molecular phenotype.

Metabolism is a particularly alluring target because it is far downstream of genetic mutations, post-translational modifications, and epigenetic alterations. It also sits very close to the tumor's molecular phenotype; many tumors rely heavily on metabolic changes in order to grow, expand, or divide. As such, one common outcome of altered cancer cell signaling pathways is the reprogramming of metabolism.

## Metabolomics can help answer critical questions.

### *What pathways/biomarkers will delineate response?*

- Profiling reaches beyond overexpression or mutational status of an *a priori* driver or target gene to ensure "the right patient"

### *What is the basis of drug response?*

- Determine the basis of sensitivity and resistance to define new targets and treatment strategies
- Understand pathways that drive efficacy beyond the primary target

### *Is my preclinical model predictive of clinical outcome?*

- Validate key translatable features from model
- Design/refine model to reflect key tumor features and cancer genetics
- Find the best fit to the human indication

### *What are the molecular details driving cancer?*

- New targets
- New strategies for combinations



# METABOLOMICS EXPANDS THE PRECISION ONCOLOGY TOOLBOX

Tracking metabolite changes improves understanding of tumor metabolic reprogramming and can offer insight into which genetic changes are critical for driving the cancer phenotype. This type of reverse engineering is particularly useful when trying to understand and treat a tumor with a high level of heterogeneity or a high number of mutations.

Metabolic pathways may also be a strong candidate for therapeutic targeting in cancer treatments. Many successful chemotherapeutics already target metabolic pathways, either directly or through their impact on oncogenic signaling pathways.

More precise and personalized treatments targeting specific metabolic pathways may lead to better results with fewer side effects. And, by taking away the opportunity for upstream redundancy to circumvent targeted therapies, metabolism-targeting therapeutics might also reduce the chance of emergent resistance.

## Advancing Precision Oncology

Since the discovery of oncogenes and the subsequent success of targeted drug therapies, the quest to find the next key targeted therapy and associated companion diagnostics has been in full gear—fueling an aggressive effort in precision oncology. Metabolism may hold the answer.

We are already starting to see drugs directed toward metabolic targets entering into clinical trials. Metabolon has contributed to some of this work at biopharmaceutical companies.<sup>2</sup> Results from a Phase 1 trial of metabolic targeting in subjects with hematological malignancies were striking. The compound, an  $\alpha$ -ketoglutarate and pyruvate dehydrogenase inhibitor, was well tolerated (a frequent concern regarding metabolic targets) and resulted in close to a 30% response rate, with one complete response to the drug.<sup>3</sup> It remains to be seen whether this success will translate to larger cohorts, but additional clinical trials of CPI-613 are ongoing as of this writing.<sup>4</sup>

As dramatic breakthroughs in precision medicine continue and new therapies such as immunotherapy add to the clinical oncologist's knowledge and armamentarium, we expect that exploration of the metabolic basis of tumors will yield additional, vital information. Metabolomics will play a key role in that research and may soon expand the tools available to advance precision medicine for cancer.

## Supporting References

1. Yuan Y, Van Allen EM, Omberg L, et al. Assessing the clinical utility of cancer genomic and proteomic data across tumor types. *Nat Biotechnol.* 2014;32(7):644-652. doi:10.1038/nbt.2940
2. Stuart SD, Schauble A, Gupta S, et al. A strategically designed small molecule attacks alpha-ketoglutarate dehydrogenase in tumor cells through a redox process. *Cancer Metab.* 2014;2(1):4. Published 2014 Mar 10. doi:10.1186/2049-3002-2-4
3. Pardee TS, Lee K, Luddy J, et al. A phase I study of the first-in-class antimetochondrial metabolism agent, CPI-613, in patients with advanced hematologic malignancies. *Clin Cancer Res.* 2014;20(20):5255-5264. doi:10.1158/1078-0432.CCR-14-1019
4. Philip PA, Buyse ME, Alistar AT, et al. A Phase III open-label trial to evaluate efficacy and safety of CPI-613 plus modified FOLFIRINOX (mFFX) versus FOLFIRINOX (FFX) in patients with metastatic adenocarcinoma of the pancreas. *Future Oncol.* 2019;15(28):3189-3196. doi:10.2217/fon-2019-0209

**During the last 20 years, Metabolon technology powered 250+ publications on oncology.**

Raines LN, Zhao H, Wang Y, et al. PERK is a critical metabolic hub for immunosuppressive function in macrophages. *Nat Immunol.* 2022;23(3):431-445. doi:10.1038/s41590-022-01145-x

Barekatin Y, Ackroyd JJ, Yan VC, et al. Homozygous MTAP deletion in primary human glioblastoma is not associated with elevation of methylthioadenosine. *Nat Commun.* 2021;12(1):4228. Published 2021 Jul 9. doi:10.1038/s41467-021-24240-3

Guida F, Tan WY, Corbin LJ, et al. The blood metabolome of incident kidney cancer: A case-control study nested within the MetKid consortium. *PLoS Med.* 2021;18(9):e1003786. Published 2021 Sep 20. doi:10.1371/journal.pmed.1003786

Wolfe AL, Zhou Q, Toska E, et al. UDP-glucose pyrophosphorylase 2, a regulator of glycogen synthesis and glycosylation, is critical for pancreatic cancer growth. *Proc Natl Acad Sci U S A.* 2021;118(31):e21103592118. doi:10.1073/pnas.2103592118

St Paul M, Saibil SD, Han S, et al. Coenzyme A fuels T cell anti-tumor immunity. *Cell Metab.* 2021;33(12):2415-2427.e6. doi:10.1016/j.cmet.2021.11.010

Hung MH, Lee JS, Ma C, et al. Tumor methionine metabolism drives T-cell exhaustion in hepatocellular carcinoma. *Nat Commun.* 2021;12(1):1455. Published 2021 Mar 5. doi:10.1038/s41467-021-21804-1

Labbé DP, Zadra G, Yang M, et al. High-fat diet fuels prostate cancer progression by rewiring the metabolome and amplifying the MYC program. *Nat Commun.* 2019;10(1):4358. Published 2019 Sep 25. doi:10.1038/s41467-019-12298-z

Li J, Wang PY, Long NA, et al. p53 prevents doxorubicin cardiotoxicity independently of its prototypical tumor suppressor activities. *Proc Natl Acad Sci U S A.* 2019;116(39):19626-19634. doi:10.1073/pnas.1904979116

Zadra G, Ribeiro CF, Chetta P, et al. Inhibition of de novo lipogenesis targets androgen receptor signaling in castration-resistant prostate cancer [published correction appears in *Proc Natl Acad Sci U S A.* 2020 Aug 4;117(31):18893]. *Proc Natl Acad Sci U S A.* 2019;116(2):631-640. doi:10.1073/pnas.1808834116

Xu H, Lee MS, Tsai PY, et al. Ablation of insulin receptor substrates 1 and 2 suppresses Kras-driven lung tumorigenesis. *Proc Natl Acad Sci U S A.* 2018;115(16):4228-4233. doi:10.1073/pnas.1718414115

Perkins BA, Caskey CT, Brar P, et al. Precision medicine screening using whole-genome sequencing and advanced imaging to identify disease risk in adults. *Proc Natl Acad Sci U S A.* 2018;115(14):3686-3691. doi:10.1073/pnas.1706096114

Huang J, Weinstein SJ, Moore SC, et al. Serum Metabolomic Profiling of All-Cause Mortality: A Prospective Analysis in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study Cohort. *Am J Epidemiol.* 2018;187(8):1721-1732. doi:10.1093/aje/kwy017

**To learn more about how Metabolon can help your study, please contact us today.**

+1 (919) 572-1711  
[www.metabolon.com/contact-us](http://www.metabolon.com/contact-us)

617 Davis Drive, Suite 100, Morrisville, NC, 27560  
© 2023 Metabolon, Inc. All rights reserved.